Navigation Links
FDA Approves LUSEDRA(TM) (fospropofol disodium) Injection for Monitored Anesthesia Care (MAC) Sedation
Date:12/14/2008

rous tactile or painful stimulation was 7/183 (4%) for colonoscopy and 24/149 (16%) for bronchoscopy. The duration of minimal or complete unresponsiveness ranged from 2 to 16 minutes in colonoscopy patients and from 2 to 20 minutes in bronchoscopy patients.

The use of supplemental oxygen is recommended in all patients receiving LUSEDRA. Airway assistance maneuvers may be required. As with other sedative-hypnotic agents, LUSEDRA may produce additive cardio-respiratory effects when administered with other cardio-respiratory depressants such as benzodiazepines and narcotic analgesics. When LUSEDRA is used at greater than the recommended doses, the incidence of serious adverse reactions is increased.

The most common adverse reactions (reported in greater than 20%) are paresthesia and pruritis.

    Please see FDA-approved labeling text at
http://www.eisai.com/presskit.asp?ID=217 .

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain
2. FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder
3. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
4. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
5. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
6. FDA Approves First Hepatitis B Viral Load Test
7. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
10. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
11. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... ON , Feb. 27, 2015 /CNW/ - Covalon Technologies ... medical technologies company, today announced financial results for its ... For the three months ended December 31, 2014, revenue ... the quarter was $229,820 or $0.02 per share.  ... , said "I am very pleased with the significant ...
(Date:2/27/2015)... 27, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, announced today that ... Officer, will present live at VirtualInvestorConferences.com on March ... join us for this Company update," said Mr. ... commercial launch of the exVive3D Liver, Bioprinted Human ...
(Date:2/27/2015)... 2015  Uroplasty, Inc. (NASDAQ: UPI ), a ... proprietary products to treat voiding dysfunctions, today announced that ... on Tuesday, March 10, 2015. Rob Kill , ... Financial Officer, will present at 4:00 p.m. Pacific Time ... conference at the Ritz Carlton in Laguna ...
Breaking Medicine Technology:Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 2Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 3Organovo Holdings, Inc. to Provide Corporate Update and Investor Presentation in a Live, Interactive Webcast on March 5th 4Uroplasty to Participate in the 27th Annual ROTH Conference 2
... KENILWORTH, N.J., Dec. 17 Schering-Plough,Corporation (NYSE: ... that,demonstrated that Asenapine, a fast-dissolving, sublingual tablet being,developed ... placebo,and well tolerated in treating patients with acute ... mg twice daily and 10 mg twice,daily were ...
... Company Initiates Phase1b/2 Clinical Trial in Breast ... PLAINFIELD, N.J., Dec. 17 PTC,Therapeutics, Inc. ... development, and commercialization of small-molecule drugs,targeting post-transcriptional ... Phase 1 data regarding PTC299, its novel,internally ...
Cached Medicine Technology:New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 2New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 3New Study Results Show Asenapine More Effective Than Placebo in the Treatment of Acute Schizophrenia 4PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium 2PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium 3PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium 4
(Date:2/28/2015)... (PRWEB) February 28, 2015 The MCA ... across Malaysia into one platform and gears towards the ... , A series of group talks in smaller groups ... Nation Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social ... raise awareness of Malaysian youths. , Young ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... BC (PRWEB) February 28, 2015 Vancouver personal ... personal injury claims are affected by time limits. They stated ... weaken a person’s claim or even nullify it. Many a ... effects on a client’s rights under BC law. As a ... are affected by accidents should consult a personal injury lawyer ...
(Date:2/28/2015)... Pioneer Millworks reclaimed USA wood will ... Construction Materials Show, an annual, premier sustainable building event ... and top manufacturers of the latest building products, services ... sourced and manufactured by Pioneer Millworks from their Oregon ... at restaurants, hotels, retailers, and corporate offices. Nichibi ...
(Date:2/28/2015)... Kaylie Corrigan, Outdoor Supervisor at ... and current student obtaining her Masters degree in social ... forum in psychoeducation on substance use for teens at ... part of her studies. , “Even though these students ... counseling at the high school and junior high school ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2Health News:Staff at Arizona Drug Addiction Treatment Center Starts Teen Sobriety Support Group at Local High School 2
... a stroke could run a further risk of further strokes ... a new study. Recurrent// strokes could also disable nearly 50% ... the University at Chicago said” Stroke incidence and mortality are ... of this risk may be explained by a greater vascular ...
... cases of E. coli have been confirmed in Wisconsin, ... been caused by bagged spinach. One person has ... ,Governor Doyle said that 15 of the 30 ... are battling severe infection. Majority of the patients are ...
... chronic disease – myositis -- will speak to congressional staff ... the staff// hearing them on this day – designated 'Myositis ... this little-known and poorly understood disease. Internationally-known male model and ... personal friend, who is prominent in Europe and has the ...
... ever-rising obesity rates all over the world sparking many lifestyle ... just be what the doctor ordered. A pill// is soon ... risk. A mere consumption of the pill once or twice ... better glucose management, thus offsetting diabetes. ,The ...
... study at the Mayo Clinic has found that injecting an ... ,Men with abnormal digital rectal exams or elevated ... usually get prostate biopsies done. ,Nearly 16% pf the patients ... biopsy, according to a new study presented at the annual ...
... 42nd Annual Meeting of the European Association for the ... HCl), an oral// antidiabetic medication, demonstrated significant cardiovascular benefits ... C and acute coronary syndrome in patients with type ... leading cause of premature death in patients with diabetes. ...
Cached Medicine News:Health News:ACTOS Linked to Several Cardiovascular Benefits 2Health News:ACTOS Linked to Several Cardiovascular Benefits 3Health News:ACTOS Linked to Several Cardiovascular Benefits 4
... easy to configure for gravimetric calibration and ... standard method or enter your own parameters ... QualiTrace automatically manages the calibration protocol with ... balance to the software, which establishes the ...
Reservoir, High Profile, Multi Well, 8 Row, Pyramid Bottom, 32mL Available Sterile...
Reservoir, High Profile, Single Well, 384ch-format, Pyramid Bottom, 282mL Available Sterile...
Reservoir, High Profile, Single Well, 12 Row, Pyramid Bottom Available Sterile...
Medicine Products: